FusoGen Pharmaceuticals, Inc., founded in 2002, is a leading biotech company in China. The company is dedicated to the discovery, development, and commercialization of novel therapeutics against serious viral infections, such as HIV, hepatitis B, and hepatitis C, by the approach of computer drug design.

Based on the structural knowledge of existing drugs, drug targets, and their interactions, FusoGen designs drugs with superior activity and reduced toxicity. We believe this model enables FusoGen to develop better drugs in shorter time and with much reduced R&D cost.

The leading drug candidate in FusoGen's drug pipeline is Sifuvirtide, an HIV fusion inhibitor, which is currently undergoing Phase II clinical trial in China.